venetoclax 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5133	1257044-40-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: venclyxto venetoclax ABT-199 venclexta GDC-0199	Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. Molecular weight: 868.45 Formula: C45H50ClN7O7S CLOGP: 10.21 LIPINSKI: 3 HAC: 14 HDO: 3 TPSA: 172.03 ALOGS: -5.97 ROTB: 12 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

venclyxto
venetoclax
ABT-199
venclexta
GDC-0199

Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.

Molecular weight: 868.45
Formula: C45H50ClN7O7S
CLOGP: 10.21
LIPINSKI: 3
HAC: 14
HDO: 3
TPSA: 172.03
ALOGS: -5.97
ROTB: 12

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Dec. 5, 2016	EMA	AbbVie Ltd
April 11, 2016	FDA	ABBVIE INC
Sept. 20, 2019	PMDA	AbbVie GK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1185.50	21.70	821	11749	324558	50267996
Febrile neutropenia	683.77	21.70	376	12194	97291	50495263
Off label use	584.08	21.70	647	11923	473779	50118775
Neutropenia	445.65	21.70	335	12235	147630	50444924
Tumour lysis syndrome	413.01	21.70	127	12443	7294	50585260
Intentional product use issue	299.57	21.70	204	12366	76714	50515840
Hospice care	271.92	21.70	87	12483	5685	50586869
Sepsis	181.81	21.70	193	12377	132732	50459822
Thrombocytopenia	172.15	21.70	184	12386	127489	50465065
Pancytopenia	149.81	21.70	141	12429	83889	50508665
Cytopenia	147.90	21.70	62	12508	8713	50583841
COVID-19	147.26	21.70	109	12461	46553	50546001
Neutrophil count decreased	137.40	21.70	104	12466	45922	50546632
Acute myeloid leukaemia recurrent	136.35	21.70	37	12533	1353	50591201
Pneumonia	128.86	21.70	287	12283	378114	50214440
Platelet count decreased	113.01	21.70	132	12438	100594	50491960
Disease progression	104.82	21.70	124	12446	95742	50496812
Lymphadenopathy	75.01	21.70	64	12506	33435	50559119
White blood cell count decreased	74.13	21.70	116	12454	116606	50475948
Infection	72.33	21.70	143	12427	172811	50419743
Pyrexia	65.46	21.70	225	12345	379978	50212576
Acute myeloid leukaemia	63.34	21.70	42	12528	15032	50577522
Hyperuricaemia	62.28	21.70	28	12542	4652	50587902
Bone marrow transplant	62.23	21.70	17	12553	637	50591917
Pain	59.81	21.70	35	12535	578868	50013686
Myelosuppression	57.61	21.70	38	12532	13479	50579075
Blood lactate dehydrogenase increased	53.50	21.70	42	12528	19520	50573034
Allogenic stem cell transplantation	52.87	21.70	8	12562	8	50592546
Pneumonia fungal	51.68	21.70	24	12546	4296	50588258
Rhinovirus infection	49.77	21.70	22	12548	3512	50589042
Joint swelling	49.03	21.70	3	12567	245283	50347271
Drug ineffective	48.50	21.70	81	12489	819252	49773302
Aspergillus infection	46.72	21.70	26	12544	6795	50585759
Blast cell count increased	45.75	21.70	12	12558	384	50592170
Chronic lymphocytic leukaemia transformation	43.92	21.70	8	12562	41	50592513
Chronic lymphocytic leukaemia refractory	43.76	21.70	8	12562	42	50592512
Escherichia sepsis	42.53	21.70	21	12549	4303	50588251
Hospitalisation	42.36	21.70	67	12503	67870	50524684
Minimal residual disease	42.20	21.70	9	12561	114	50592440
Arthralgia	41.84	21.70	29	12541	438673	50153881
Hyperphosphataemia	41.10	21.70	16	12554	1855	50590699
Bone marrow failure	41.00	21.70	42	12528	27582	50564972
Non-small cell lung cancer	40.44	21.70	18	12552	2919	50589635
Anaemia	38.68	21.70	144	12426	252312	50340242
Septic shock	37.89	21.70	58	12512	57117	50535437
Headache	34.81	21.70	45	12525	506490	50086064
COVID-19 pneumonia	34.32	21.70	23	12547	8372	50584182
Pleural effusion	33.55	21.70	67	12503	81387	50511167
Swelling	33.47	21.70	5	12565	200867	50391687
Escherichia bacteraemia	33.24	21.70	16	12554	3100	50589454
Rash	33.11	21.70	36	12534	437435	50155119
Atrial fibrillation	33.05	21.70	76	12494	101669	50490885
Transformation to acute myeloid leukaemia	32.99	21.70	8	12562	185	50592369
Blood phosphorus increased	32.93	21.70	15	12555	2567	50589987
Febrile bone marrow aplasia	32.51	21.70	20	12550	6291	50586263
Myelodysplastic syndrome	32.01	21.70	28	12542	15104	50577450
Soft tissue infection	30.84	21.70	13	12557	1849	50590705
Product dose omission issue	29.67	21.70	5	12565	183833	50408721
Nasopharyngitis	29.53	21.70	6	12564	192921	50399633
Autoimmune haemolytic anaemia	29.47	21.70	16	12554	3983	50588571
Drug hypersensitivity	29.07	21.70	13	12557	250997	50341557
Blood uric acid increased	27.31	21.70	15	12555	3819	50588735
Cerebral haemorrhage	26.27	21.70	33	12537	27019	50565535
Fungal sepsis	25.81	21.70	10	12560	1144	50591410
Stem cell transplant	25.49	21.70	11	12559	1657	50590897
Nonspecific reaction	24.81	21.70	11	12559	1768	50590786
Bronchopulmonary aspergillosis	24.50	21.70	18	12552	7574	50584980
Maternal exposure during pregnancy	24.38	21.70	5	12565	159773	50432781
Colitis	24.00	21.70	38	12532	38491	50554063
Terminal ileitis	23.87	21.70	8	12562	603	50591951
Abdominal discomfort	23.83	21.70	14	12556	231627	50360927
Campylobacter gastroenteritis	23.37	21.70	7	12563	366	50592188
Chronic lymphocytic leukaemia recurrent	23.15	21.70	6	12564	183	50592371
Hypophosphataemia	22.86	21.70	18	12552	8396	50584158
Splenomegaly	22.73	21.70	19	12551	9641	50582913
Lymphocyte count decreased	22.28	21.70	30	12540	26277	50566277
Subacute combined cord degeneration	22.01	21.70	6	12564	223	50592331
Prolymphocytic leukaemia	21.90	21.70	3	12567	0	50592554
Peripheral swelling	21.82	21.70	12	12558	205924	50386630

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1417.14	18.69	1484	20611	340600	29211832
Off label use	896.00	18.69	1104	20991	299696	29252736
Tumour lysis syndrome	738.59	18.69	305	21790	13579	29538853
Febrile neutropenia	654.79	18.69	592	21503	111648	29440784
Neutropenia	473.64	18.69	535	21560	131176	29421256
Intentional product use issue	434.49	18.69	312	21783	42186	29510246
Hospice care	398.80	18.69	148	21947	4920	29547512
COVID-19	304.37	18.69	236	21859	35778	29516654
Pneumonia	181.95	18.69	587	21508	319585	29232847
Cytopenia	178.92	18.69	104	21991	9755	29542677
Sepsis	154.08	18.69	333	21762	142349	29410083
Disease progression	151.27	18.69	241	21854	81675	29470757
Thrombocytopenia	147.08	18.69	316	21779	134507	29417925
Pancytopenia	139.10	18.69	234	21861	82934	29469498
Infection	131.06	18.69	218	21877	76533	29475899
Lymphadenopathy	129.45	18.69	124	21971	24925	29527507
Neutrophil count decreased	107.48	18.69	147	21948	43420	29509012
Platelet count decreased	100.13	18.69	233	21862	104439	29447993
Autoimmune haemolytic anaemia	81.70	18.69	45	22050	3803	29548629
Hyperphosphataemia	79.29	18.69	37	22058	2201	29550231
Chronic lymphocytic leukaemia recurrent	78.49	18.69	23	22072	355	29552077
Lymphocyte count increased	77.30	18.69	39	22056	2755	29549677
Transplant	76.21	18.69	26	22069	671	29551761
Acute myeloid leukaemia recurrent	74.33	18.69	33	22062	1747	29550685
Pyrexia	72.62	18.69	413	21682	287209	29265223
Myelosuppression	71.76	18.69	65	22030	12162	29540270
COVID-19 pneumonia	70.88	18.69	58	22037	9464	29542968
Pneumonia fungal	69.59	18.69	47	22048	5730	29546702
Splenomegaly	67.17	18.69	65	22030	13214	29539218
Chronic lymphocytic leukaemia	65.03	18.69	38	22057	3595	29548837
Toxicity to various agents	63.82	18.69	25	22070	173636	29378796
White blood cell count decreased	59.26	18.69	166	21929	83196	29469236
Blood phosphorus increased	57.01	18.69	32	22063	2805	29549627
Completed suicide	55.18	18.69	3	22092	90243	29462189
Hospitalisation	53.66	18.69	111	21984	45877	29506555
Acute myeloid leukaemia	52.12	18.69	63	22032	16450	29535982
Bacteraemia	51.07	18.69	62	22033	16261	29536171
Soft tissue infection	49.84	18.69	25	22070	1744	29550688
Product dose omission issue	48.79	18.69	7	22088	96376	29456056
Septic shock	47.84	18.69	128	21967	62432	29490000
Hyperuricaemia	47.20	18.69	40	22055	6849	29545583
Neutropenic sepsis	45.88	18.69	50	22045	11677	29540755
Lymphocytosis	44.83	18.69	24	22071	1916	29550516
Blast cell count increased	43.29	18.69	19	22076	978	29551454
Skin infection	40.87	18.69	36	22059	6491	29545941
Blood pressure increased	40.70	18.69	4	22091	73799	29478633
Drug interaction	40.43	18.69	53	22042	197332	29355100
Mantle cell lymphoma refractory	39.87	18.69	10	22085	82	29552350
Stem cell transplant	38.81	18.69	22	22073	1965	29550467
Headache	37.43	18.69	45	22050	173962	29378470
Blast cell count decreased	37.20	18.69	6	22089	0	29552432
Somnolence	37.07	18.69	12	22083	93943	29458489
Leukaemia	36.60	18.69	27	22068	3783	29548649
Bone marrow transplant	34.72	18.69	16	22079	924	29551508
Blood uric acid increased	34.50	18.69	31	22064	5737	29546695
Minimal residual disease	34.42	18.69	12	22083	331	29552101
Hypogammaglobulinaemia	33.86	18.69	31	22064	5876	29546556
Anaemia	33.75	18.69	261	21834	200690	29351742
Blood lactate dehydrogenase increased	33.28	18.69	55	22040	19154	29533278
Hypocalcaemia	32.93	18.69	57	22038	20608	29531824
Chronic lymphocytic leukaemia transformation	32.69	18.69	10	22085	180	29552252
Condition aggravated	32.34	18.69	37	22058	146258	29406174
Chemotherapy	32.23	18.69	13	22082	541	29551891
Squamous cell carcinoma	32.16	18.69	39	22056	10212	29542220
Overdose	31.83	18.69	10	22085	79809	29472623
Myelodysplastic syndrome	30.90	18.69	51	22044	17743	29534689
Allogenic stem cell transplantation	30.62	18.69	6	22089	12	29552420
Blood uric acid abnormal	30.21	18.69	8	22087	83	29552349
Full blood count abnormal	30.16	18.69	46	22049	14967	29537465
Depression	30.03	18.69	13	22082	85134	29467298
Weight increased	29.88	18.69	10	22085	76657	29475775
Tremor	29.71	18.69	9	22086	73529	29478903
Haemolysis	29.58	18.69	31	22064	6925	29545507
Bronchopulmonary aspergillosis	29.42	18.69	41	22054	12303	29540129
Escherichia bacteraemia	29.15	18.69	21	22074	2837	29549595
Pain in extremity	28.95	18.69	24	22071	110409	29442023
Pruritus	28.70	18.69	27	22068	116822	29435610
Anxiety	28.60	18.69	14	22081	85351	29467081
Acute myeloid leukaemia refractory	28.19	18.69	6	22089	21	29552411
Pain	27.56	18.69	54	22041	171378	29381054
Atrial fibrillation	26.66	18.69	152	21943	105494	29446938
Mantle cell lymphoma recurrent	26.63	18.69	11	22084	487	29551945
Influenza	26.44	18.69	80	22015	41801	29510631
Chronic lymphocytic leukaemia refractory	25.66	18.69	7	22088	82	29552350
Lymphocyte count decreased	25.44	18.69	49	22046	19222	29533210
White blood cell count abnormal	24.81	18.69	19	22076	2816	29549616
Coronavirus infection	24.40	18.69	20	22075	3268	29549164
Rash	23.96	18.69	68	22027	189751	29362681
Dizziness	23.90	18.69	68	22027	189616	29362816
Arthralgia	23.29	18.69	43	22052	139574	29412858
Hallucination	23.20	18.69	3	22092	44709	29507723
Agitation	23.17	18.69	5	22090	51299	29501133
Haemoglobin abnormal	22.99	18.69	19	22076	3142	29549290
General physical health deterioration	22.14	18.69	142	21953	102715	29449717
Gait disturbance	21.73	18.69	14	22081	73335	29479097
Fungal sepsis	21.52	18.69	11	22084	798	29551634
Cellulitis	21.33	18.69	79	22016	45761	29506671
Drug ineffective	21.15	18.69	172	21923	362998	29189434
Transfusion reaction	20.85	18.69	11	22084	852	29551580
International normalised ratio increased	20.71	18.69	4	22091	44368	29508064
Aspergillus infection	20.66	18.69	32	22063	10549	29541883
Joint swelling	20.17	18.69	6	22089	49624	29502808
Transfusion	20.08	18.69	26	22069	7272	29545160
Angiodysplasia	19.76	18.69	9	22086	506	29551926
Respiratory tract infection	19.69	18.69	39	22056	15612	29536820
Seizure	19.03	18.69	25	22070	93098	29459334
Hypercalcaemia	18.78	18.69	34	22061	12725	29539707

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1404.27	18.50	1364	27128	481341	63988899
Febrile neutropenia	1370.13	18.50	912	27580	186745	64283495
Tumour lysis syndrome	1018.19	18.50	366	28126	19074	64451166
Neutropenia	798.26	18.50	733	27759	238891	64231349
Off label use	694.31	18.50	1097	27395	631709	63838531
Pneumonia	376.78	18.50	787	27705	558789	63911451
Sepsis	373.59	18.50	483	28009	229858	64240382
Thrombocytopenia	325.41	18.50	445	28047	223356	64246884
COVID-19	288.04	18.50	235	28257	64905	64405335
Cytopenia	274.87	18.50	135	28357	15336	64454904
Neutrophil count decreased	257.31	18.50	237	28255	76959	64393281
Intentional product use issue	236.30	18.50	249	28243	95115	64375125
Pancytopenia	206.45	18.50	284	28208	143025	64327215
Platelet count decreased	200.21	18.50	304	28188	167407	64302833
Infection	175.47	18.50	302	28190	184578	64285662
Lymphadenopathy	174.55	18.50	153	28339	46533	64423707
Hospice care	170.57	18.50	78	28414	7547	64462693
Disease progression	167.86	18.50	256	28236	141424	64328816
Acute myeloid leukaemia recurrent	166.79	18.50	58	28434	2726	64467514
Pyrexia	156.66	18.50	571	27921	558073	63912167
Myelosuppression	129.08	18.50	97	28395	23733	64446507
White blood cell count decreased	121.96	18.50	236	28256	157601	64312639
Hyperphosphataemia	115.84	18.50	49	28443	3932	64466308
Pneumonia fungal	113.14	18.50	62	28430	8815	64461425
Hyperuricaemia	113.11	18.50	65	28427	10126	64460114
COVID-19 pneumonia	102.55	18.50	73	28419	16431	64453809
Septic shock	95.65	18.50	169	28323	105268	64364972
Pain	93.96	18.50	65	28427	553446	63916794
Autoimmune haemolytic anaemia	89.02	18.50	49	28443	7027	64463213
Bacteraemia	88.33	18.50	82	28410	26829	64443411
Anaemia	86.97	18.50	364	28128	378316	64091924
Acute myeloid leukaemia	86.91	18.50	82	28410	27381	64442859
Chronic lymphocytic leukaemia recurrent	85.80	18.50	24	28468	542	64469698
Soft tissue infection	84.98	18.50	37	28455	3186	64467054
Blood lactate dehydrogenase increased	84.71	18.50	88	28404	32990	64437250
Blast cell count increased	81.87	18.50	28	28464	1251	64468989
Toxicity to various agents	78.89	18.50	31	28461	363482	64106758
Blood phosphorus increased	78.50	18.50	40	28452	4906	64465334
Splenomegaly	75.52	18.50	63	28429	17898	64452342
Joint swelling	72.70	18.50	6	28486	215376	64254864
Atrial fibrillation	72.45	18.50	202	28290	170887	64299353
Lymphocytosis	71.34	18.50	34	28458	3610	64466630
Arthralgia	68.49	18.50	57	28435	442203	64028037
Allogenic stem cell transplantation	67.87	18.50	12	28480	23	64470217
Headache	67.41	18.50	81	28411	529386	63940854
Escherichia sepsis	62.13	18.50	39	28453	7126	64463114
Escherichia bacteraemia	61.40	18.50	35	28457	5368	64464872
Blood pressure increased	60.53	18.50	4	28488	172548	64297692
Chronic lymphocytic leukaemia	60.18	18.50	32	28460	4283	64465957
Rhinovirus infection	57.16	18.50	35	28457	6121	64464119
Bronchopulmonary aspergillosis	56.62	18.50	55	28437	19030	64451210
Pruritus	55.17	18.50	35	28457	312365	64157875
Product dose omission issue	54.61	18.50	10	28482	194737	64275503
Rash	52.34	18.50	76	28416	458473	64011767
Myelodysplastic syndrome	51.11	18.50	62	28430	27517	64442723
Nasopharyngitis	50.99	18.50	12	28480	196061	64274179
Lymphocyte count increased	50.63	18.50	30	28462	4945	64465295
Chronic lymphocytic leukaemia transformation	50.01	18.50	13	28479	220	64470020
Drug ineffective	49.28	18.50	198	28294	840049	63630191
Aspergillus infection	48.21	18.50	47	28445	16332	64453908
Skin infection	47.76	18.50	45	28447	14992	64455248
Hypogammaglobulinaemia	47.23	18.50	38	28454	10261	64459979
Chronic lymphocytic leukaemia refractory	47.21	18.50	11	28481	115	64470125
Pain in extremity	46.94	18.50	39	28453	303046	64167194
Squamous cell carcinoma	46.94	18.50	43	28449	13826	64456414
Febrile bone marrow aplasia	46.32	18.50	39	28453	11216	64459024
Hypocalcaemia	45.92	18.50	73	28419	41680	64428560
Blood uric acid increased	45.91	18.50	34	28458	8129	64462111
Swelling	45.40	18.50	8	28484	160210	64310030
Drug interaction	43.30	18.50	58	28434	362025	64108215
Drug hypersensitivity	42.86	18.50	26	28466	237789	64232451
Neutropenic sepsis	42.60	18.50	52	28440	23220	64447020
Minimal residual disease	42.52	18.50	13	28479	404	64469836
Somnolence	41.50	18.50	19	28473	203626	64266614
Condition aggravated	40.27	18.50	64	28428	372362	64097878
Overdose	39.12	18.50	11	28481	159555	64310685
Mantle cell lymphoma refractory	38.13	18.50	9	28483	100	64470140
Weight increased	37.50	18.50	24	28468	213324	64256916
Leukaemia	37.48	18.50	25	28467	5063	64465177
Respiratory failure	36.90	18.50	155	28337	161028	64309212
Dizziness	36.84	18.50	85	28407	430078	64040162
Anxiety	36.72	18.50	22	28470	202627	64267613
Urticaria	36.40	18.50	10	28482	147307	64322933
Bone marrow transplant	34.66	18.50	15	28477	1272	64468968
Blood uric acid abnormal	34.64	18.50	9	28483	152	64470088
Depression	34.49	18.50	19	28473	183272	64286968
Hypoaesthesia	33.34	18.50	10	28482	139098	64331142
Synovitis	32.76	18.50	3	28489	99087	64371153
Abdominal discomfort	32.74	18.50	20	28472	182302	64287938
Hyperkalaemia	32.08	18.50	108	28384	101021	64369219
Multiple organ dysfunction syndrome	31.90	18.50	108	28384	101305	64368935
Tremor	31.51	18.50	13	28479	148217	64322023
Maternal exposure during pregnancy	31.44	18.50	3	28489	95881	64374359
Asthma	31.17	18.50	3	28489	95222	64375018
Fungal sepsis	31.03	18.50	15	28477	1643	64468597
Bacterial sepsis	31.02	18.50	26	28466	7431	64462809
Hospitalisation	31.00	18.50	88	28404	75119	64395121
Inappropriate schedule of product administration	29.96	18.50	3	28489	92283	64377957
Klebsiella sepsis	29.77	18.50	17	28475	2615	64467625
Rhabdomyolysis	29.74	18.50	3	28489	91723	64378517
Cellulitis	29.69	18.50	100	28392	93557	64376683
Transplant	29.58	18.50	12	28480	866	64469374
Gait disturbance	29.39	18.50	20	28472	172135	64298105
General physical health deterioration	29.24	18.50	172	28320	204253	64265987
Contraindicated product administered	29.23	18.50	6	28486	107823	64362417
Pleural effusion	29.19	18.50	122	28370	126437	64343803
Lymphocyte count decreased	29.12	18.50	59	28433	40640	64429600
Systemic toxicity	29.08	18.50	7	28485	85	64470155
Respiratory tract infection	28.90	18.50	56	28436	37351	64432889
Hypophosphataemia	28.76	18.50	34	28458	14686	64455554
Peripheral swelling	28.72	18.50	30	28462	209123	64261117
Bone marrow failure	27.98	18.50	64	28428	47888	64422352
Infusion related reaction	26.90	18.50	20	28472	164447	64305793
Blast cells	26.90	18.50	4	28488	0	64470240
Campylobacter gastroenteritis	26.80	18.50	12	28480	1104	64469136
Feeling abnormal	26.39	18.50	13	28479	133589	64336651
Pneumocystis jirovecii pneumonia	25.94	18.50	45	28447	27589	64442651
Transfusion reaction	25.25	18.50	13	28479	1628	64468612
Full blood count abnormal	24.78	18.50	46	28446	29711	64440529
Therapeutic product effect decreased	24.70	18.50	10	28482	115341	64354899
White blood cell count abnormal	24.60	18.50	19	28473	4835	64465405
Non-small cell lung cancer	24.48	18.50	19	28473	4871	64465369
Flushing	24.41	18.50	3	28489	78645	64391595
Malaise	23.99	18.50	92	28400	396155	64074085
Chest discomfort	23.38	18.50	11	28481	116095	64354145
Erythema	23.32	18.50	29	28463	187041	64283199
Transformation to acute myeloid leukaemia	23.08	18.50	10	28482	851	64469389
Hypersensitivity	22.91	18.50	32	28460	196420	64273820
Wheezing	22.87	18.50	4	28488	80575	64389665
Vascular device infection	22.56	18.50	20	28472	6160	64464080
Insomnia	22.31	18.50	33	28459	197803	64272437
Leukaemia recurrent	22.19	18.50	14	28478	2580	64467660
Sinusitis fungal	21.97	18.50	12	28480	1694	64468546
Hypercalcaemia	21.83	18.50	45	28447	31371	64438869
Pseudomonal sepsis	21.44	18.50	18	28474	5154	64465086
Acute myeloid leukaemia refractory	21.31	18.50	5	28487	54	64470186
Colitis	20.71	18.50	65	28427	58609	64411631
General physical condition abnormal	20.53	18.50	18	28474	5464	64464776
Chemotherapy	20.52	18.50	11	28481	1496	64468744
Coronavirus infection	20.40	18.50	18	28474	5512	64464728
Alopecia	20.32	18.50	26	28466	165664	64304576
Angiodysplasia	20.18	18.50	9	28483	820	64469420
Clostridium colitis	20.04	18.50	13	28479	2512	64467728
Herpes simplex	20.03	18.50	24	28468	10512	64459728
Agitation	20.02	18.50	7	28485	88360	64381880
Blood product transfusion dependent	19.77	18.50	7	28485	347	64469893
Chondrocalcinosis pyrophosphate	19.50	18.50	11	28481	1653	64468587
Wound	19.25	18.50	5	28487	76472	64393768
Terminal ileitis	19.03	18.50	8	28484	632	64469608
Wrong technique in product usage process	18.94	18.50	3	28489	64971	64405269
Paraesthesia	18.79	18.50	19	28473	134503	64335737
Platelet disorder	18.71	18.50	12	28480	2275	64467965
Bradycardia	18.54	18.50	15	28477	118204	64352036

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX52	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
FDA PE	N0000009176	Increased Cellular Death
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA EPC	N0000192515	BCL-2 Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:68495	Type I cell-death inducers
CHEBI has role	CHEBI:133022	B-cell lymphoma 2 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Acute myeloid leukemia, disease	indication	91861009
Chronic lymphoid leukemia, disease	indication	92814006
Malignant lymphoma - small lymphocytic	indication	302841002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.0	acidic
pKa2	13.01	acidic
pKa3	7.73	Basic
pKa4	4.24	Basic
pKa5	3.47	Basic
pKa6	0.56	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9174982	May 26, 2030	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	10993942	Sept. 6, 2033	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	11110087	Sept. 6, 2033	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	11110087	Sept. 6, 2033	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9539251	Sept. 6, 2033	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	10993942	Sept. 6, 2033	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	11110087	Sept. 6, 2033	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	11110087	Sept. 6, 2033	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9539251	Sept. 6, 2033	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	10993942	Sept. 6, 2033	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	11110087	Sept. 6, 2033	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	11110087	Sept. 6, 2033	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	9539251	Sept. 6, 2033	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	May 15, 2022	VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	May 15, 2022	VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	May 15, 2022	VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	April 11, 2023	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	April 11, 2023	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	April 11, 2023	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	Oct. 16, 2023	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	Oct. 16, 2023	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	Oct. 16, 2023	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	June 8, 2025	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	June 8, 2025	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	June 8, 2025	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	Nov. 21, 2025	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	Nov. 21, 2025	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	Nov. 21, 2025	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	May 15, 2026	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	May 15, 2026	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
50MG	VENCLEXTA	ABBVIE INC	N208573	April 11, 2016	RX	TABLET	ORAL	May 15, 2026	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Apoptosis regulator Bcl-2	Cytosolic other	P10415	BCL2_HUMAN	INHIBITOR	Ki	11	SCIENTIFIC LITERATURE	DRUG LABEL
Aspartyl/asparaginyl beta-hydroxylase	Enzyme	Q12797	ASPH_HUMAN		IC50	5.89	CHEMBL
Bcl-2-like protein 1	Cytosolic other	Q07817	B2CL1_HUMAN	INHIBITOR	Ki	7.32	SCIENTIFIC LITERATURE
Apoptosis regulator Bcl-W	Cytosolic other	Q92843	B2CL2_HUMAN	INHIBITOR	Ki	6.61	SCIENTIFIC LITERATURE

External reference:

ID	Source
N54AIC43PW	UNII
D10679	KEGG_DRUG
4035629	VANDF
C4079830	UMLSCUI
CHEBI:133021	CHEBI
LBM	PDB_CHEM_ID
CHEMBL3137309	ChEMBL_ID
49846579	PUBCHEM_CID
DB11581	DRUGBANK_ID
9925	INN_ID
8318	IUPHAR_LIGAND_ID
1747556	RXNORM
240227	MMSL
31601	MMSL
d08429	MMSL
720491001	SNOMEDCT_US
763511000	SNOMEDCT_US
016803	NDDF
C579720	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Venclexta	HUMAN PRESCRIPTION DRUG LABEL	1	0074-0561	TABLET, FILM COATED	10 mg	ORAL	NDA	31 sections
Venclexta	HUMAN PRESCRIPTION DRUG LABEL	1	0074-0566	TABLET, FILM COATED	50 mg	ORAL	NDA	31 sections
Venclexta	HUMAN PRESCRIPTION DRUG LABEL	1	0074-0576	TABLET, FILM COATED	100 mg	ORAL	NDA	31 sections